Piper Sandler maintains Solventum at Overweight, raises price target to $110 from $105

Piper Sandler kept Solventum's rating at Overweight and increased its price target to $110 from $105, suggesting a 26.2% upside from the Nov 5 close of $87.18.

Original reporting
Published Nov 6, 2026, 2:26 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 2:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Piper Sandler maintains Solventum at Overweight, raises price target to $110 from $105 — source image
Decision brief

The 30-second read

Low
01

Why it matters

The upgrade suggests a modest upside but limited market impact given the small size of the company.

02

Market read

A modest analyst upgrade with a small price target increase; limited immediate trading relevance.

03

What to watch

Potential hidden risk if the analyst's assumptions change.

Relevance 5/10Novelty 5/10Timing: today

Background

Piper Sandler upgraded Solventum to Overweight and lifted its price target from $105 to $110.

Market effects

none

none

none

Counterpoint

No strong contrarian case; price target raise is modest.

Key entities

  • Piper Sandler

    Equity research firm providing the rating and price target.

Related articles

$SOLVMedAI 8/10

SOLV Energy Q3 Revenue Rises 65% to $1.24 Billion; Raises 2026 Guidance

SOLV Energy reported Q3 2026 revenue of $1.24B, up 65% YoY, with net income of $123M. Adjusted EBITDA was $173M, and gross margin was 17.8%. The company raised its 2026 guidance for revenue, adjusted gross profit, and adjusted EBITDA. Growth was driven by new construction and existing infrastructure revenue. SOLV completed its acquisition of ASB Energy Services in October 2026.

$SOLVMed

Solventum (SOLV) stock trades up, here is why

Solventum (SOLV) shares rose 5% after reporting Q3 2026 revenue of $1.95B and EPS of $1.45, and raising full-year EPS guidance to $7.20-$7.30. The company completed ERP cutovers and exited 90% of transition agreements with 3M. Shares cooled to $91.19, up 4.6% from the previous close.

$SOLVMed

Solventum Q3 Earnings Call Highlights

Solventum reported Q3 sales of $1.9B, with mixed performance across segments. Gross margin rose to 57.1%, while operating margin fell to 19.9%. The company raised its full-year earnings outlook to $7.20-$7.30 per share and expects high-end organic sales growth. It also announced plans to separate its Health Information Systems business and renegotiated a raw material supply agreement with 3M.

MedAI 8/10

Solventum Earnings Call Signals Stronger Growth Ahead

Solventum Corporation (SOLV) reported Q3 earnings, highlighting strong execution despite ERP transition challenges. Sales were $1.95B, down 7% YoY, but organic growth was ~4% excluding ERP timing reversals. Gross margin rose to 57.1%, and full-year EPS guidance was raised to $7.20-$7.30. The 3M separation is 90% complete, with margin expansion and cost savings driving growth.